379 related articles for article (PubMed ID: 34437720)
41. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
Chuang CC; Guillemin I; Bachert C; Lee SE; Hellings PW; Fokkens WJ; Duverger N; Fan C; Daizadeh N; Amin N; Mannent LP; Khan AH; Kamat S
Laryngoscope; 2022 Feb; 132(2):259-264. PubMed ID: 34817082
[TBL] [Abstract][Full Text] [Related]
42. Chronic Rhinosinusitis Patients With and Without Polyps Experience Different Symptom Perception and Quality of Life Burdens.
Talat R; Speth MM; Gengler I; Phillips KM; Caradonna DS; Gray ST; Sedaghat AR
Am J Rhinol Allergy; 2020 Nov; 34(6):742-750. PubMed ID: 32437223
[TBL] [Abstract][Full Text] [Related]
43. Exploring possibilities for shortening the 22-item Sino-Nasal Outcome Test (SNOT-22) using item response theory.
Liu DT; Phillips KM; Speth MM; Besser G; Mueller CA; Sedaghat AR
Int Forum Allergy Rhinol; 2022 Feb; 12(2):191-199. PubMed ID: 34448367
[TBL] [Abstract][Full Text] [Related]
44. Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review.
Nitro L; Bulfamante AM; Rosso C; Saibene AM; Arnone F; Felisati G; Pipolo C
Acta Otorhinolaryngol Ital; 2022 Jun; 42(3):199-204. PubMed ID: 35880360
[TBL] [Abstract][Full Text] [Related]
45. Predictors of efficacy for combination oral and topical corticosteroids to treat patients with chronic rhinosinusitis with nasal polyps.
Epperson MV; Phillips KM; Caradonna DS; Gray ST; Sedaghat AR
Int Forum Allergy Rhinol; 2019 Dec; 9(12):1436-1442. PubMed ID: 31609091
[TBL] [Abstract][Full Text] [Related]
46. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
[TBL] [Abstract][Full Text] [Related]
47. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP.
Desrosiers M; Mannent LP; Amin N; Canonica GW; Hellings PW; Gevaert P; Mullol J; Lee SE; Fujieda S; Han JK; Hopkins C; Fokkens W; Jankowski R; Cho SH; Mao X; Zhang M; Rice MS; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Bachert C
Rhinology; 2021 Jun; 59(3):301-311. PubMed ID: 33847325
[TBL] [Abstract][Full Text] [Related]
48. Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.
Boyle JV; Lam K; Han JK
Immunotherapy; 2020 Feb; 12(2):111-121. PubMed ID: 32075470
[TBL] [Abstract][Full Text] [Related]
49. Development and Validation of the Sinonasal Outcome Test-12.
Al Sharhan SS; Al Bar MH; Al Saied AS; Al Somali MI; Abdel Wahab MM
J Prim Care Community Health; 2023; 14():21501319231189060. PubMed ID: 37501403
[TBL] [Abstract][Full Text] [Related]
50. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
[TBL] [Abstract][Full Text] [Related]
51. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
Tversky J; Lane AP; Azar A
Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
[TBL] [Abstract][Full Text] [Related]
52. [Experience of biological therapy in severe forms of chronic rhinosinusitis with nasal polyps in the conditions of regional healthcare].
Larin RA; Mokeeva PP; Grishin AS
Vestn Otorinolaringol; 2023; 88(2):51-58. PubMed ID: 37184555
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.
Hopkins C; Wagenmann M; Bachert C; Desrosiers M; Han JK; Hellings PW; Lee SE; Msihid J; Radwan A; Rowe P; Amin N; Deniz Y; Ortiz B; Mannent LP; Rout R
Int Forum Allergy Rhinol; 2021 Jul; 11(7):1087-1101. PubMed ID: 33611847
[TBL] [Abstract][Full Text] [Related]
54. Doxycycline may be more clinically effective in type 2 chronic rhinosinusitis nasal polyp comorbid with asthma.
Paçacı Çetin G; Arslan B; Yılmaz İ
J Asthma; 2024 Jan; 61(1):20-26. PubMed ID: 37437223
[TBL] [Abstract][Full Text] [Related]
55. Dupilumab (Dupixent
Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
[TBL] [Abstract][Full Text] [Related]
56. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months.
van der Lans RJL; Otten JJ; Adriaensen GFJPM; Hoven DR; Benoist LB; Fokkens WJ; Reitsma S
Allergy; 2023 Oct; 78(10):2684-2697. PubMed ID: 37394895
[TBL] [Abstract][Full Text] [Related]
57. A validated model for the 22-item Sino-Nasal Outcome Test subdomain structure in chronic rhinosinusitis.
Feng AL; Wesely NC; Hoehle LP; Phillips KM; Yamasaki A; Campbell AP; Gregorio LL; Killeen TE; Caradonna DS; Meier JC; Gray ST; Sedaghat AR
Int Forum Allergy Rhinol; 2017 Dec; 7(12):1140-1148. PubMed ID: 29028287
[TBL] [Abstract][Full Text] [Related]
58. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
Fujieda S; Matsune S; Takeno S; Ohta N; Asako M; Bachert C; Inoue T; Takahashi Y; Fujita H; Deniz Y; Rowe P; Ortiz B; Li Y; Mannent LP
Allergy; 2022 Jan; 77(1):186-196. PubMed ID: 33993501
[TBL] [Abstract][Full Text] [Related]
59. Development and Preliminary Validation of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO).
Ghadersohi S; Price CPE; Jensen SE; Beaumont JL; Kern RC; Conley DB; Welch KC; Peters AT; Grammer LC; Stevens WW; Calice AM; Stanton E; VanderMeeden MK; Schleimer RP; Tan BK
J Allergy Clin Immunol Pract; 2020; 8(7):2341-2350.e1. PubMed ID: 32376490
[TBL] [Abstract][Full Text] [Related]
60. Validation of the Sino-Nasal Outcome Test 20 (SNOT-20) domains in nonsurgical patients.
Pynnonen MA; Kim HM; Terrell JE
Am J Rhinol Allergy; 2009; 23(1):40-5. PubMed ID: 19379611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
